All
Keytruda Granted Priority Review for Advanced Gastric Cancer
May 25th 2017Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.
Keytruda Approved for Any Solid Tumor With a Specific Genetic Marker
May 24th 2017Keytruda (pembrolizumab) was granted an accelerated approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients who have unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors.
New Breast Cancer Agent Shows Promise in an Early Trial
May 23rd 2017Early results for a new agent, pyrotinib (HTI-1001), are showing promise for the treatment of HER2-positive breast cancer, according to phase 1 results from China published in the Journal of Clinical Oncology, which showed that the drug was well-tolerated and showed anti-tumor activity.
Stem Cell Transplant Benefit Limited for Some Patients With Lymphoma
May 23rd 2017There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous stem-cell transplantation to reduce the risk of relapse, but the jury is still out on the impact that it has.
Despite Benefits, HPV Vaccination Rates Remain Too Low
May 18th 2017Despite impressive efficacy for the human papillomavirus (HPV) vaccine reducing the prevalence of high-risk oral HPV infections by 88 percent, many young adults still are not getting the vaccine – sparking concern in the health community.